Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints oncology development head

Dr Fouad Namouni promoted from head of medical

BMS Dr Fouad NamouniBristol-Myers Squibb has promoted Dr Fouad Namouni to oncology development head.

In his new role, Dr Namouni will oversee the development strategy for the pharmaceutical firm's oncology pipeline from early stage development through to commercialisation.

He will remain a member of the research and development leadership team, reporting to chief scientific officer and executive vice president Francis Cuss.

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions in research and development.

On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab). He most recently served as head of medical.

Cuss said: “Fouad has demonstrated highly successful strategic and visionary leadership in oncology and immuno-oncology drug development and medical affairs throughout his career at Bristol-Myers Squibb.

“As a trained pediatric oncologist, Fouad brings to this role exceptional clinical experience and an unwavering commitment to patients.

“I am confident that our oncology development programmes will continue to thrive under his leadership.”

27th July 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...